

Dyskinesia Therapeutics Pipeline Industry H1 2016

"Dyskinesia - Pipeline Review, H1 2016" new report to its research database. The report provides an overview of the Dyskinesia pipeline landscape.

PUNE, INDIA, May 4, 2016 /EINPresswire.com/ -- The report "[Dyskinesia - Pipeline Review, H1 2016](#)" provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.



Complete Report Details Available at <https://www.wiseguyreports.com/reports/dyskinesia-pipeline-review-h1-2016> .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain

competitive advantage.

Inquire more about this report at <https://www.wiseguyreports.com/enquiry/dyskinesia-pipeline-review-h1-2016> .

Dyskinesia - Companies Involved in Therapeutics Development:

Adamas Pharmaceuticals, Inc.

Addex Therapeutics Ltd

Advicenne Pharma

Amarantus Bioscience Holdings, Inc.

Astraea Therapeutics, LLC

Bionomics Limited

Catalyst Biosciences, Inc.

Catalyst Pharmaceutical Partners, Inc.

Clevexel Pharma SAS

Contera Pharma ApS

EpiVax, Inc.

Heptares Therapeutics Limited

Hua Medicine Ltd.

Integrative Research Laboratories Sweden AB

Ipsen S.A.

Merz Pharma GmbH & Co. KgaA

MitoDys Therapeutics Limited

Neurim Pharmaceuticals Ltd

Neurocrine Biosciences, Inc.

Neurolix Inc.

Osmotica Pharmaceutical Corp.

Otsuka Holdings Co., Ltd.

Phenomenome Discoveries, Inc.

Revance Therapeutics, Inc.

Sage Therapeutics, Inc.

Santhera Pharmaceuticals Holding AG

SciFluor Life Sciences, LLC

SOM Innovation Biotech SL

Synchroneuron Inc.

Teva Pharmaceutical Industries Limited

Get a sample copy at <https://www.wiseguyreports.com/sample-request/dyskinesia-pipeline-review-h1-2016> .

Scope

- The report provides a snapshot of the global therapeutic landscape of Dyskinesia
- The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research

institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects
- The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dyskinesia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a Purchase Report Copy @

https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=443151 .

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

16468459349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/324526018>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.